Characteristics of Patients with Psoriatic Arthritis Receiving Secukinumab and Reasons for Initiation: A US Retrospective Medical Chart Review
Abstract Introduction Secukinumab is a fully human anti-interleukin 17A monoclonal antibody approved for the treatment of psoriatic arthritis (PsA) in the United States. Few studies have investigated prescribing patterns among rheumatologists who have initiated secukinumab for the treatment of patie...
Guardat en:
| Autors principals: | , , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Adis, Springer Healthcare
2019-01-01
|
| Col·lecció: | Rheumatology and Therapy |
| Matèries: | |
| Accés en línia: | http://link.springer.com/article/10.1007/s40744-018-0137-z |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|